EGFR and neoplasm: Therapies targeting several genes, including EGFR-TKI (13, 22, 23), ALK-TKIs (24), MET-TKIs (25), antiangiogenic therapy (26, 27) and immune-checkpoint inhibitors (21, 28), were tested in patients with PSC, although given the rarity of the tumor type, large scale studies of any particular therapy may never be completed.